Concepts (213)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nervous System Diseases | 5 | 2016 | 370 | 1.060 |
Why?
|
| Liability, Legal | 2 | 2016 | 44 | 1.020 |
Why?
|
| Malpractice | 2 | 2016 | 55 | 1.010 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 4 | 2018 | 30 | 0.950 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2016 | 254 | 0.880 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2023 | 19 | 0.870 |
Why?
|
| Neurology | 2 | 2023 | 108 | 0.800 |
Why?
|
| Glioblastoma | 2 | 2018 | 333 | 0.780 |
Why?
|
| Social Media | 1 | 2023 | 107 | 0.740 |
Why?
|
| Terminal Care | 2 | 2019 | 114 | 0.720 |
Why?
|
| Medicaid | 1 | 2023 | 244 | 0.720 |
Why?
|
| Medicare | 1 | 2023 | 423 | 0.670 |
Why?
|
| Brain Neoplasms | 2 | 2018 | 1217 | 0.640 |
Why?
|
| Herpesvirus 3, Human | 1 | 2018 | 26 | 0.600 |
Why?
|
| Interferon beta-1a | 1 | 2017 | 18 | 0.590 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2017 | 32 | 0.580 |
Why?
|
| Drug Eruptions | 2 | 2016 | 33 | 0.560 |
Why?
|
| Dermatologic Agents | 1 | 2016 | 30 | 0.540 |
Why?
|
| Compensation and Redress | 1 | 2016 | 12 | 0.530 |
Why?
|
| Central Nervous System Agents | 1 | 2016 | 15 | 0.530 |
Why?
|
| Negotiating | 1 | 2016 | 9 | 0.520 |
Why?
|
| Expert Testimony | 1 | 2016 | 36 | 0.520 |
Why?
|
| Morals | 1 | 2016 | 67 | 0.500 |
Why?
|
| Mental Disorders | 2 | 2014 | 827 | 0.490 |
Why?
|
| Truth Disclosure | 1 | 2016 | 103 | 0.480 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 234 | 0.470 |
Why?
|
| Lymphoma | 1 | 2017 | 322 | 0.460 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2013 | 21 | 0.440 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2013 | 12 | 0.430 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2014 | 48 | 0.430 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2013 | 3518 | 0.420 |
Why?
|
| Autoantibodies | 3 | 2017 | 422 | 0.410 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2014 | 128 | 0.410 |
Why?
|
| Anti-Retroviral Agents | 1 | 2014 | 135 | 0.410 |
Why?
|
| Brain Infarction | 1 | 2012 | 30 | 0.410 |
Why?
|
| Cerebral Hemorrhage | 1 | 2013 | 142 | 0.410 |
Why?
|
| Corpus Callosum | 1 | 2012 | 98 | 0.400 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 3 | 2017 | 148 | 0.400 |
Why?
|
| Scleroderma, Systemic | 1 | 2013 | 117 | 0.390 |
Why?
|
| Limbic Encephalitis | 1 | 2011 | 4 | 0.370 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2011 | 68 | 0.370 |
Why?
|
| Toxoplasmosis | 1 | 2011 | 19 | 0.370 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2011 | 18 | 0.360 |
Why?
|
| Neurocysticercosis | 2 | 2011 | 25 | 0.360 |
Why?
|
| Sneddon Syndrome | 1 | 2010 | 3 | 0.360 |
Why?
|
| Humans | 38 | 2023 | 123180 | 0.360 |
Why?
|
| Immunologic Factors | 2 | 2014 | 180 | 0.350 |
Why?
|
| Peripheral Nervous System | 1 | 2010 | 42 | 0.350 |
Why?
|
| Pelvic Floor | 1 | 2010 | 34 | 0.350 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2011 | 138 | 0.340 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2011 | 230 | 0.320 |
Why?
|
| Central Nervous System | 1 | 2010 | 253 | 0.320 |
Why?
|
| Isaacs Syndrome | 1 | 2008 | 1 | 0.310 |
Why?
|
| Cyclophosphamide | 1 | 2010 | 420 | 0.300 |
Why?
|
| Electromyography | 1 | 2008 | 160 | 0.290 |
Why?
|
| Antitubercular Agents | 1 | 2010 | 349 | 0.280 |
Why?
|
| Emotions | 1 | 2010 | 364 | 0.280 |
Why?
|
| Memory | 1 | 2010 | 360 | 0.270 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 645 | 0.260 |
Why?
|
| Fatal Outcome | 4 | 2017 | 357 | 0.250 |
Why?
|
| Brain Diseases | 1 | 2006 | 294 | 0.220 |
Why?
|
| Tuberculosis | 1 | 2010 | 573 | 0.220 |
Why?
|
| United States | 5 | 2023 | 10618 | 0.220 |
Why?
|
| Fraud | 1 | 2023 | 16 | 0.220 |
Why?
|
| Antipsychotic Agents | 2 | 2011 | 375 | 0.220 |
Why?
|
| Privacy | 1 | 2023 | 26 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2021 | 2043 | 0.210 |
Why?
|
| Middle Aged | 10 | 2021 | 25980 | 0.210 |
Why?
|
| Confidentiality | 1 | 2023 | 103 | 0.200 |
Why?
|
| Palliative Care | 2 | 2019 | 428 | 0.200 |
Why?
|
| Computer Communication Networks | 1 | 2022 | 15 | 0.200 |
Why?
|
| Female | 19 | 2021 | 65428 | 0.200 |
Why?
|
| Chlorpromazine | 1 | 2001 | 12 | 0.200 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2014 | 141 | 0.190 |
Why?
|
| Hyperpigmentation | 1 | 2001 | 13 | 0.190 |
Why?
|
| Mobile Health Units | 1 | 2021 | 24 | 0.190 |
Why?
|
| Ambulances | 1 | 2021 | 23 | 0.190 |
Why?
|
| Cerebral Angiography | 2 | 2013 | 101 | 0.190 |
Why?
|
| Emergency Medical Services | 2 | 2021 | 434 | 0.190 |
Why?
|
| International Cooperation | 1 | 2022 | 160 | 0.180 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2012 | 169 | 0.180 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 112 | 0.180 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 186 | 0.170 |
Why?
|
| Male | 14 | 2021 | 60022 | 0.170 |
Why?
|
| Adult | 12 | 2017 | 29039 | 0.150 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2017 | 61 | 0.140 |
Why?
|
| Brain Injuries | 2 | 2016 | 734 | 0.140 |
Why?
|
| Neurologists | 1 | 2017 | 17 | 0.140 |
Why?
|
| Teratoma | 1 | 2017 | 123 | 0.130 |
Why?
|
| Job Satisfaction | 1 | 2017 | 78 | 0.130 |
Why?
|
| Civil Rights | 1 | 2016 | 10 | 0.130 |
Why?
|
| History, Medieval | 1 | 2016 | 26 | 0.130 |
Why?
|
| Unconsciousness | 1 | 2016 | 17 | 0.130 |
Why?
|
| History, Ancient | 1 | 2016 | 54 | 0.130 |
Why?
|
| Virtues | 1 | 2016 | 20 | 0.130 |
Why?
|
| Ethical Analysis | 1 | 2016 | 48 | 0.130 |
Why?
|
| Beneficence | 1 | 2016 | 81 | 0.130 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 149 | 0.120 |
Why?
|
| Graves Disease | 1 | 2015 | 16 | 0.120 |
Why?
|
| Hyperthyroidism | 1 | 2015 | 26 | 0.120 |
Why?
|
| Burnout, Professional | 1 | 2017 | 115 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 1872 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 197 | 0.120 |
Why?
|
| Alzheimer Disease | 1 | 2022 | 766 | 0.120 |
Why?
|
| Injections, Intravenous | 2 | 2014 | 252 | 0.110 |
Why?
|
| Polyradiculoneuropathy | 1 | 2013 | 6 | 0.110 |
Why?
|
| Occipital Lobe | 1 | 2013 | 32 | 0.110 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 407 | 0.110 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2014 | 80 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2015 | 12103 | 0.110 |
Why?
|
| Psychotic Disorders | 1 | 2015 | 140 | 0.110 |
Why?
|
| Plasma Exchange | 1 | 2014 | 83 | 0.110 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2017 | 443 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 2838 | 0.100 |
Why?
|
| Laminectomy | 1 | 2011 | 25 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2014 | 379 | 0.090 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 455 | 0.090 |
Why?
|
| Neurologic Examination | 1 | 2011 | 192 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 62 | 0.090 |
Why?
|
| Electroencephalography | 2 | 2013 | 862 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1229 | 0.090 |
Why?
|
| Benzodiazepines | 1 | 2011 | 101 | 0.090 |
Why?
|
| Pregnancy Complications | 1 | 2015 | 507 | 0.090 |
Why?
|
| Frontotemporal Lobar Degeneration | 1 | 2010 | 7 | 0.090 |
Why?
|
| Young Adult | 3 | 2014 | 8870 | 0.090 |
Why?
|
| Verbal Learning | 1 | 2010 | 66 | 0.090 |
Why?
|
| Rituximab | 1 | 2011 | 156 | 0.080 |
Why?
|
| Williams Syndrome | 1 | 2009 | 39 | 0.080 |
Why?
|
| Executive Function | 1 | 2010 | 104 | 0.080 |
Why?
|
| Social Perception | 1 | 2009 | 57 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 1088 | 0.080 |
Why?
|
| Amygdala | 1 | 2009 | 81 | 0.080 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2011 | 265 | 0.080 |
Why?
|
| Neurosurgical Procedures | 1 | 2011 | 297 | 0.080 |
Why?
|
| Skin Diseases | 1 | 2010 | 122 | 0.080 |
Why?
|
| Attention | 1 | 2010 | 194 | 0.080 |
Why?
|
| Critical Care | 1 | 2014 | 650 | 0.080 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 281 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1240 | 0.070 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2007 | 14 | 0.070 |
Why?
|
| Lumbosacral Region | 1 | 2007 | 33 | 0.070 |
Why?
|
| Rehabilitation | 1 | 2007 | 29 | 0.070 |
Why?
|
| Electrophysiology | 1 | 2008 | 268 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 1117 | 0.070 |
Why?
|
| Physical and Rehabilitation Medicine | 1 | 2007 | 33 | 0.070 |
Why?
|
| Learning | 1 | 2010 | 361 | 0.070 |
Why?
|
| Neuropsychological Tests | 1 | 2010 | 921 | 0.070 |
Why?
|
| Disasters | 1 | 2007 | 99 | 0.070 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2010 | 463 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 5048 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 1115 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 936 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2021 | 1245 | 0.050 |
Why?
|
| Animals | 2 | 2016 | 33728 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 1677 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 82 | 0.050 |
Why?
|
| Tobramycin | 1 | 2001 | 23 | 0.050 |
Why?
|
| Piperacillin | 1 | 2001 | 13 | 0.050 |
Why?
|
| Epilepsy | 1 | 2009 | 859 | 0.050 |
Why?
|
| Erythema | 1 | 2001 | 24 | 0.050 |
Why?
|
| Ciprofloxacin | 1 | 2001 | 66 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2021 | 190 | 0.040 |
Why?
|
| Penicillins | 1 | 2001 | 154 | 0.040 |
Why?
|
| Aged | 4 | 2022 | 19072 | 0.040 |
Why?
|
| Netherlands | 1 | 2019 | 36 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2001 | 266 | 0.040 |
Why?
|
| Depersonalization | 1 | 2017 | 8 | 0.040 |
Why?
|
| Cognition | 1 | 2022 | 735 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2019 | 680 | 0.030 |
Why?
|
| Fatigue | 1 | 2017 | 217 | 0.030 |
Why?
|
| Personal Autonomy | 1 | 2017 | 201 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 298 | 0.030 |
Why?
|
| Cerebrospinal Fluid | 1 | 2014 | 92 | 0.030 |
Why?
|
| Pregnancy | 2 | 2017 | 7124 | 0.030 |
Why?
|
| Hydrolases | 1 | 2013 | 52 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1418 | 0.030 |
Why?
|
| Adolescent | 2 | 2008 | 19087 | 0.030 |
Why?
|
| Autoantigens | 1 | 2013 | 120 | 0.030 |
Why?
|
| Biomarkers | 1 | 2022 | 2943 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2022 | 4709 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2013 | 243 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 640 | 0.020 |
Why?
|
| Time Factors | 1 | 2001 | 6201 | 0.020 |
Why?
|
| Prevalence | 1 | 2017 | 2405 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1683 | 0.020 |
Why?
|
| Age Factors | 1 | 2017 | 2801 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 426 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2001 | 2397 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 587 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 280 | 0.020 |
Why?
|
| Social Behavior | 1 | 2009 | 207 | 0.020 |
Why?
|
| Self Concept | 1 | 2009 | 157 | 0.020 |
Why?
|
| Skin Ulcer | 1 | 2007 | 32 | 0.020 |
Why?
|
| Louisiana | 1 | 2007 | 135 | 0.020 |
Why?
|
| Quality of Life | 1 | 2017 | 1932 | 0.020 |
Why?
|
| Disaster Planning | 1 | 2007 | 65 | 0.020 |
Why?
|
| Musculoskeletal Diseases | 1 | 2007 | 55 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2009 | 229 | 0.020 |
Why?
|
| Brain | 1 | 2017 | 2947 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1799 | 0.020 |
Why?
|
| Pain Management | 1 | 2007 | 174 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8089 | 0.010 |
Why?
|
| Pain | 1 | 2007 | 470 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2007 | 363 | 0.010 |
Why?
|
| Mass Screening | 1 | 2009 | 790 | 0.010 |
Why?
|
| Texas | 1 | 2011 | 3548 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2011 | 15981 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 2001 | 90 | 0.010 |
Why?
|
| Depression | 1 | 2009 | 1225 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2001 | 204 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 3662 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2007 | 6372 | 0.010 |
Why?
|
| Risk Factors | 1 | 2010 | 10000 | 0.010 |
Why?
|